FDAnews Drug Daily Bulletin

The FDA has OKed Pfizer’s Bosulif, a once-daily pill to treat chronic myelogenous leukemia (CML), marking the pharma giant’s third new oncology drug approval in a little more than a year. Bosulif (bosutinib), a kinase inhibitor, is indicated for patients with chronic, accelerated or blast phase Philadelphia chromosome positive CML who are resistant to or cannot tolerate other therapies, including Novartis’ Gleevec (imatinib). The drug helps block the development of abnormal and unhealthy white blood cells.
Washington Drug Letter